×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IBRX – immunitybio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IBRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
10:22 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Low
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
12/12
08:00 am
ibrx
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
Medium
Report
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
12/11
07:30 am
ibrx
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
High
Report
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
12/10
04:29 pm
ibrx
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
High
Report
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
12/10
04:24 pm
ibrx
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
High
Report
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
11/25
08:30 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Low
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
11/22
05:27 am
ibrx
ImmunityBio and nCartes partner to automate clinical trial data processes [Yahoo! Finance]
Low
Report
ImmunityBio and nCartes partner to automate clinical trial data processes [Yahoo! Finance]
11/21
10:07 am
ibrx
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment [Yahoo! Finance]
Medium
Report
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
07:37 pm
ibrx
Form 4 ImmunityBio, Inc. For: Dec 15 Filed by: LAUER REGAN J
Medium
Report
Form 4 ImmunityBio, Inc. For: Dec 15 Filed by: LAUER REGAN J
12/12
09:21 pm
ibrx
Form 4 ImmunityBio, Inc. For: Dec 10 Filed by: SOON-SHIONG PATRICK
Medium
Report
Form 4 ImmunityBio, Inc. For: Dec 10 Filed by: SOON-SHIONG PATRICK
12/11
07:47 am
ibrx
Form 8-K ImmunityBio, Inc. For: Dec 10
Medium
Report
Form 8-K ImmunityBio, Inc. For: Dec 10
12/10
05:29 pm
ibrx
Form 8-K ImmunityBio, Inc. For: Dec 10
High
Report
Form 8-K ImmunityBio, Inc. For: Dec 10
11/19
08:02 am
ibrx
Form 8-K ImmunityBio, Inc. For: Nov 19
Medium
Report
Form 8-K ImmunityBio, Inc. For: Nov 19
11/12
09:33 am
ibrx
Form 8-K ImmunityBio, Inc. For: Nov 12
Medium
Report
Form 8-K ImmunityBio, Inc. For: Nov 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: